<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, excess energy intake on the background of genetic predisposition and lifestyle factors leads to the dysregulation of fatty acid metabolism and acquired <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>These initial metabolic defects are reflected to both <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> and <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and contribute to increased risk for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, even after controlling for the traditional <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>, subjects with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> remain at high residual cardiovascular risk despite of low/<z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> concentration </plain></SENT>
<SENT sid="3" pm="."><plain>For 2 decades, <z:chebi fb="0" ids="35664">statin</z:chebi> therapy has been the cornerstone of treatment of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> in these disorders </plain></SENT>
<SENT sid="4" pm="."><plain>In the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, only <z:chebi fb="0" ids="35664">statin</z:chebi> treatment has demonstrated consistently a significant reduction in cardiovascular and <z:hpo ids='HP_0000001'>all</z:hpo> cause mortality in clinical trials </plain></SENT>
<SENT sid="5" pm="."><plain>Lately, increased incidence of <z:mp ids='MP_0002055'>diabetes</z:mp> especially in the high-risk populations using <z:chebi fb="0" ids="35664">statins</z:chebi> has raised the debate whether <z:chebi fb="0" ids="35664">statins</z:chebi> are indicated for primary prevention especially in the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Guidelines recommend intensified lifestyle intervention to those in high risk groups on <z:chebi fb="0" ids="35664">statin</z:chebi> therapy to reduce the residual risk </plain></SENT>
<SENT sid="7" pm="."><plain>Despite of the proven efficacy on plasma <z:chebi fb="23" ids="18059">lipids</z:chebi>, fibrate, or niacin as monotherapy, or in combination with <z:chebi fb="0" ids="35664">statins</z:chebi> has failed in reducing cardiovascular mortality </plain></SENT>
<SENT sid="8" pm="."><plain>This underlies the fact that improvement in <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> or other biomarkers is not equal to the reduction in cardiovascular events </plain></SENT>
<SENT sid="9" pm="."><plain>However, fibrates in combination with <z:chebi fb="0" ids="35664">statins</z:chebi> seem to be beneficial to reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> events in subjects with <z:hpo ids='HP_0003233'>low HDL-cholesterol</z:hpo> (&lt; 0.9-1.1 mmol/L) and elevated <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (&gt; 2.3 mmol/L), but the data are derived from subgroup analysis of clinical trials </plain></SENT>
<SENT sid="10" pm="."><plain>The position of niacin and <z:chebi fb="0" ids="49040">ezetimibe</z:chebi> and <z:chebi fb="6" ids="25681">omega-3 fatty acids</z:chebi> in treatment of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> in the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is even less clear and remains to be established in future clinical trials </plain></SENT>
</text></document>